Oncolytics Biotech (ONCY) Meets Primary Endpoint in Phase 2 Trial of REOLYSIN Early
Tweet Send to a Friend
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced Monday that its Phase 2 trial of intravenous administration of REOLYSIN with gemcitabine in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
